DC
ABEO icon

Diametric Capital’s Abeona Therapeutics ABEO Stock Holding History

Diametric Capital’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.74M Sell
611,520
-82,901
-12% -$414K 0.71% 21
2025
Q4 		$3.66M Buy
694,421
+521,220
+301% +$2.62M 0.98% 14
2025
Q3 		$915K Buy
173,201
+34,838
+25% +$221K 0.34% 70
2025
Q2 		$786K Buy
138,363
+119,609
+638% +$681K 0.42% 62
2025
Q1 		$89.3K Buy
+18,754
New +$102K 0.11% 175

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Diametric Capital's ABEO Position: Q1 2026 in Review

Diametric Capital reduced its Abeona Therapeutics (ABEO) stake by 12% in Q1 2026, selling an estimated $414K and leaving 611,520 shares worth $2.74M. The position accounts for 0.71% of the portfolio, ranked #21.

Diametric Capital first reported a position in ABEO in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.66M in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Diametric Capital held 611,520 shares of Abeona Therapeutics worth $2.74M as of Q1 2026.
  • Diametric Capital sold 82,901 Abeona Therapeutics shares in Q1 2026, an estimated $414K.
  • Abeona Therapeutics made up 0.71% of Diametric Capital's portfolio in Q1 2026, its #21 holding.
  • Diametric Capital first reported a position in Abeona Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Diametric Capital's Abeona Therapeutics position peaked at $3.66M in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.